Vasculitis & polymyalgia rheumatica
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood‐Onset Anti‐Neutrophil Cytoplasmic Antibody‐Associated Vasculitis: An ARChiVe Registry Cohort Study
Authors' conclusion
No significant differences were shown in rates of remission, severe adverse events, or organ damage.
Study context
- Population
- Patients with childhood granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) from A Registry of Childhood Vasculitis (ARChiVe)43% rituximab (RTX), 46% CYC, 11% both
- Participants
- 104 patients
- Exposure
- RTX vs CYC for induction therapy
- Outcome
- Postinduction remission (Pediatric Vasculitis Activity Score (PVAS) = 0) or low disease activity (PVAS ≤ 2)
Methodological detailsretrospective, comparative, logistic regression, ordinal regression
- Retrospective
- Comparative
- Logistic regression
- Ordinal regression
Main finding
As reported in the abstract
Postinduction remission (PVAS = 0) or low disease activity (PVAS ≤ 2), odds of achieving remission
- No difference in remission among the groups (63% overall)
Observational data: associations, not effects.
Further findings
Median
| Outcome | RTX | CYC | OR (95% CI) | |
|---|---|---|---|---|
| pVDI score · 12 monthsRTXvs CYCOrdinal regression | 1 | 1 | 0.98 (0.43–2.22) | |
| 0.512Odds ratio (log scale) |
Safety
| Outcome | RTX | CYC | OR (95% CI) | |
|---|---|---|---|---|
| Hospital admission for adverse eventsRTXvs CYC | 22% | 10% | 2.27 (0.73–7.05) | |
| 0.10.31310Odds ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood‐Onset Anti‐Neutrophil Cytoplasmic Antibody‐Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). Published 10 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →